Maria Jäntti

Ph.D. (Biol.)
Post doctoral researcher

Dr. Maria Jäntti joined PREP lab on fall 2017. Her project is testing novel PREP ligands in different models of neurodegenerative diseases.


M.Sc. (Biol.), University of Oulu, Finland, 2009
Ph.D. (Biol.), University of Helsinki, Finland, 2015


Virpi Talman, Alessia Pascale, Maria Jäntti, Marialaura Amadio, Raimo K. Tuominen  Protein Kinase C Activation as a Potential Therapeutic Strategy in Alzheimer’s Disease: Is there a Role for Embryonic Lethal Abnormal Vision-like Proteins? Basic Clin Pharmacol Toxicol, 119: 149-60, 2015

Louhivuori LM, Jansson L, Turunen PM, Jäntti MH, Nordström T, Louhivuori V, Åkerman KE. Transient receptor potential channels and their role in modulating radial glial-neuronal interaction: a signaling pathway involving mGluR5. Stem Cells Dev. 24:701-13, 2015.

Jäntti MH, Mandrika I, Kukkonen JP. Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors. Biochem Biophys Res Commun. 445:486-90, 2014

Jäntti MH, Putula J, Turunen PM, Näsman J, Reijonen S, Lindqvist C, Kukkonen JP. Autocrine endocannabinoid signaling through CB1 receptors potentiates OX1 orexin receptor signaling. Mol Pharmacol. 83:621-32, 2013

Turunen PM, Jäntti MH, Kukkonen JP. OX1 orexin/hypocretin receptor signaling through arachidonic acid and endocannabinoid release. Mol Pharmacol. 82:156-67, 2012

Jäntti MH, Putula J, Somerharju P, Frohman MA, Kukkonen JP. OX1 orexin/hypocretin receptor activation of phospholipase D. Br J Pharmacol. 165: 1109-23, 2012

Putula J, Turunen PM, Jäntti MH, Ekholm ME, Kukkonen JP. Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett. 494: 57-60. 2011